These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35738024)

  • 1. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Othman T; Moskoff BN; Ho G; Tenold ME; Azenkot T; Krackeler ML; Fisch SC; Potter LA; Kaesberg PR; Welborn JL; Wun T; Esteghamat NS; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
    Leuk Res; 2022 Aug; 119():106885. PubMed ID: 35738024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
    Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
    Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
    Ribera JM; Prawitz T; Freitag A; Sharma A; Dobi B; Rizzo F; Sabatelli L; Patos P
    Adv Ther; 2023 Jul; 40(7):3087-3103. PubMed ID: 37208556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
    Kantarjian H; Short NJ; Jain N; Sasaki K; Huang X; Haddad FG; Khouri I; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Kebriaei P; Garris R; Loghavi S; Jorgensen J; Kwari M; O'Brien S; Ravandi F; Jabbour E
    Am J Hematol; 2023 Mar; 98(3):493-501. PubMed ID: 36600670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
    Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Sasaki K; Kantarjian HM; Morita K; Short NJ; Konopleva M; Jain N; Ravandi F; Garcia-Manero G; Wang S; Khoury JD; Jorgensen JL; Champlin RE; Khouri IF; Kebriaei P; Schroeder HM; Khouri M; Garris R; Takahashi K; O'Brien SM; Jabbour EJ
    Cancer; 2021 Sep; 127(18):3381-3389. PubMed ID: 34138471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
    Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
    Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
    Sasaki Y; Kantarjian HM; Short NJ; Wang F; Furudate K; Uryu H; Garris R; Jain N; Sasaki K; Ravandi F; Konopleva M; Garcia-Manero G; Little L; Gumbs C; Zhao L; Futreal PA; Takahashi K; Jabbour E
    Leukemia; 2022 May; 36(5):1253-1260. PubMed ID: 35132195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
    Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
    J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
    Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
    Zarling LC; Stevenson PA; Soma LA; Martino CH; Percival MM; Halpern AB; Ghiuzeli CM; Becker PS; Oehler VG; Cooper JP; Orozco JJ; Hendrie PC; Walter RB; Estey EH; Cassaday RD
    Eur J Haematol; 2023 Dec; 111(6):863-871. PubMed ID: 37670560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.